{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:29:09Z","timestamp":1781803749046,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007682","name":"Medicinski Fakultet, Sveu\u010dili\u0161te u Zagrebu","doi-asserted-by":"publisher","award":["KK01.1.1.01.0008"],"award-info":[{"award-number":["KK01.1.1.01.0008"]}],"id":[{"id":"10.13039\/501100007682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mammary carcinogenesis is partly regulated by the transforming growth factor beta (TGF\u03b2) signaling pathway. Its function in cancer progression and metastasis is highly dependent on disease stage, and it is likely modulated by the ratio of membrane-bound vs. soluble TGF\u03b2rIII (sTGF\u03b2rIII). In this prospective observational study, we assessed tissue expression and plasma levels of sTGF\u03b2rIII in healthy women, women with benign breast lesions and in early-stage breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a preliminary study, plasma sTGF\u03b2rIII levels were determined in 13 healthy women (age 19\u201340\u00a0years) at different phases of the ovarian cycle, and in 15 patients (age 35\u201375\u00a0years) at different times of the day. The main study assessed plasma concentrations of sTGF\u03b2rIII in: (i) 158 healthy women in whom breast lesions were excluded; (ii) 65 women with benign breast lesions; (iii) 147 women with newly diagnosed breast cancer classified as American Joint Committee on Cancer (AJCC) stages 0 to IIB. Completers provided blood samples before surgery and at 10\u201330 and 160\u2013180\u00a0days after surgery. Plasma sTGF\u03b2rIII concentrations were determined using an indirect ELISA kit. Part of the removed tissues underwent immunohistochemical (IHC) staining and analysis of tissue TGF\u03b2rIII expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There appeared no relevant variations in plasma sTGF\u00dfrIII levels at different times of the day or different ovarian cycle phases. Before surgery, breast cancer patients had somewhat higher sTGF\u03b2rIII than healthy women, or those with benign breast lesions (by 14.5 and 26\u00a0ng\/mL, respectively), with a tendency of larger differences at higher age. This correlated with lower expression of TGF\u03b2rIII in breast cancer vs. healthy tissue samples. At 160\u2013180\u00a0days after surgery, plasma sTGF\u03b2rIII levels in breast cancer patients declined by 23\u201326\u00a0ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma sTGF\u03b2rIII levels do not seem to relevantly vary during the day or the ovarian cycle. The coinciding higher plasma levels in newly diagnosed cancer patients than in healthy subjects and lower TGF\u03b2rIII expression in the malignant than in healthy breast tissue suggest ectodomain shedding as a source of circulating sTGF\u03b2rIII. Decline in plasma levels after tumor removal supports such a view.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-020-02659-4","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T08:04:58Z","timestamp":1607673898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Plasma levels and tissue expression of soluble TGF\u03b2rIII receptor in women with early-stage breast cancer and in healthy women: a prospective observational study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9814-3178","authenticated-orcid":false,"given":"Lovorka","family":"Grgurevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruder","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Hrkac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grgur","family":"Salai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josko","family":"Bilandzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla Ferhatovic","family":"Hamzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiha","family":"Vucemilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita Peric","family":"Balja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmen","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"issue":"2","key":"2659_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-010-1032-7","volume":"125","author":"X-H Chen","year":"2011","unstructured":"Chen X-H, Li X-Q, Chen Y, Feng Y-M. Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat. 2011;125(2):575\u201382.","journal-title":"Breast Cancer Res Treat"},{"key":"2659_CR2","doi-asserted-by":"crossref","unstructured":"O. Alanazi I, Khan Z. Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis. Breast Cancer Surg. 2018;.","DOI":"10.5772\/intechopen.74679"},{"key":"2659_CR3","doi-asserted-by":"crossref","unstructured":"Kumar R, Panwar D, Amirtham U, Premalata C, Gopal C, Narayana S, et al. Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India. South Asian J Cancer [Internet]. 2018 Jan 1;7(1):7\u201310. Available from: http:\/\/journal.sajc.org\/article.asp?issn=2278-330X.","DOI":"10.4103\/sajc.sajc_211_17"},{"key":"2659_CR4","doi-asserted-by":"crossref","unstructured":"Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga J-Y, et al. Circulating Tumor Cells in Early Breast Cancer. JNCI cancer Spectr. 2019 Jun;3(2):pkz026.","DOI":"10.1093\/jncics\/pkz026"},{"issue":"1","key":"2659_CR5","doi-asserted-by":"publisher","first-page":"16979","DOI":"10.1038\/s41598-019-53606-3","volume":"9","author":"A Ivars Rubio","year":"2019","unstructured":"Ivars Rubio A, Yufera JC, de la Morena P, Fern\u00e1ndez S\u00e1nchez A, Navarro Manzano E, Garc\u00eda Garre E, et al. Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables. Sci Rep. 2019;9(1):16979.","journal-title":"Sci Rep"},{"key":"2659_CR6","doi-asserted-by":"crossref","unstructured":"Huang JJ, Corona AL, Dunn BP, Cai EM, Prakken JN, Blobe GC. Increased type III TGF-\u03b2 receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. Oncogene [Internet]. 2019 May 14;38(18):3402\u201314. Available from: http:\/\/www.nature.com\/articles\/s41388-018-0672-7.","DOI":"10.1038\/s41388-018-0672-7"},{"issue":"3","key":"2659_CR7","first-page":"200","volume":"33","author":"D Jurisic","year":"2015","unstructured":"Jurisic D, Erjavec I, Trkulja V, Dumic-Cule I, Hadzibegovic I, Kovacevic L, et al. Soluble type III TGF \u03b2 receptor in diagnosis and follow-up of patients with breast cancer. Growth Factors. 2015;33(3):200\u20139.","journal-title":"Growth Factors"},{"issue":"15","key":"2659_CR8","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1073\/pnas.1633291100","volume":"100","author":"AB Roberts","year":"2003","unstructured":"Roberts AB, Wakefield LM. The two faces of transforming growth factor \u03b2 in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100(15):8621\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2659_CR9","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.cellsig.2010.01.016","volume":"22","author":"CE Gatza","year":"2010","unstructured":"Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-\u03b2 receptor in human cancer. Cell Signal. 2010;22(8):1163\u201374.","journal-title":"Cell Signal"},{"issue":"1","key":"2659_CR10","first-page":"699","volume":"17","author":"S Liu","year":"2018","unstructured":"Liu S, Chen S, Zeng J. TGF-\u03b2 signaling: a complex role in tumorigenesis (Review). Mol Med Rep. 2018;17(1):699\u2013704.","journal-title":"Mol Med Rep"},{"key":"2659_CR11","doi-asserted-by":"crossref","unstructured":"Jenkins LM, Horst B, Lancaster CL, Mythreye K. Dually modified transmembrane proteoglycans in development and disease. Cytokine Growth Factor Rev [Internet]. 2018;39(December):124\u201336. http:\/\/dx.doi.org\/10.1016\/j.cytogfr.2017.12.003.","DOI":"10.1016\/j.cytogfr.2017.12.003"},{"issue":"1","key":"2659_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1172\/JCI29293","volume":"117","author":"M Dong","year":"2007","unstructured":"Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, et al. The type III TGF-\u03b2 receptor suppresses breast cancer progression. J Clin Invest. 2007;117(1):206\u201317.","journal-title":"J Clin Invest"},{"issue":"16","key":"2659_CR13","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1091\/mbc.e13-09-0524","volume":"25","author":"JL Elderbroom","year":"2014","unstructured":"Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, et al. Ectodomain shedding of T\u03b2RIII is required for T\u03b2RIII-mediated suppression of TGF-\u03b2 signaling and breast cancer migration and invasion. Mol Biol Cell. 2014;25(16):2320\u201332.","journal-title":"Mol Biol Cell"},{"key":"2659_CR14","doi-asserted-by":"crossref","unstructured":"Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-\u03b2 receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest [Internet]. 2013\/08\/08. 2013 Sep;123(9):3925\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/23925295.","DOI":"10.1172\/JCI65745"},{"issue":"19","key":"2659_CR15","first-page":"5041","volume":"59","author":"A Bandyopadhyay","year":"1999","unstructured":"Bandyopadhyay A, Zhu Y, Cibull ML, Bao LW, Chen C, Sun LZ. A soluble transforming growth factor \u03b2 type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res. 1999;59(19):5041\u20136.","journal-title":"Cancer Res"},{"issue":"16","key":"2659_CR16","first-page":"4690","volume":"62","author":"A Bandyopadhyay","year":"2002","unstructured":"Bandyopadhyay A, L\u00f3pez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. 2002;62(16):4690\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"2659_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/abbs\/gmx123","volume":"50","author":"F Xie","year":"2018","unstructured":"Xie F, Ling L, Van Dam H, Zhou F, Zhang L. TGF-\u03b2 signaling in cancer metastasis. Acta Biochim Biophys Sin. 2018;50(1):121\u201332.","journal-title":"Acta Biochim Biophys Sin"},{"key":"2659_CR18","doi-asserted-by":"crossref","unstructured":"Zarzynska JM. Two faces of TGF-beta1 in breast cancer. Mediators Inflamm [Internet]. 2014\/05\/07. 2014;2014:141747. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24891760.","DOI":"10.1155\/2014\/141747"},{"key":"2659_CR19","doi-asserted-by":"crossref","unstructured":"Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC. The Balance of Cell Surface and Soluble Type III TGF-\u03b2 Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells. Neoplasia [Internet]. 2014;16(6):489\u2013500. http:\/\/dx.doi.org\/10.1016\/j.neo.2014.05.008.","DOI":"10.1016\/j.neo.2014.05.008"},{"issue":"11","key":"2659_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers8110100","volume":"8","author":"B Jovanovi\u0107","year":"2016","unstructured":"Jovanovi\u0107 B, Pickup MW, Chytil A, Gorska AE, Johnson KC, Moses HL, et al. T\u03b2RIII expression in human breast cancer stroma and the role of soluble T\u03b2RIII in breast cancer associated fibroblasts. Cancers. 2016;8(11):1\u201318.","journal-title":"Cancers"},{"key":"2659_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2017.07.002","author":"S Winters","year":"2017","unstructured":"Winters S, Martin C, Murphy D, Breast Shokar NK, Epidemiology Cancer. Prevention, and Screening [Internet]. Vol. 151, Progress in Molecular Biology and Translational Science. Elsevier Inc. Elsevier Inc. 2017. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.07.002.","journal-title":"Elsevier Inc"},{"issue":"4","key":"2659_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/GRF.0000000000000239","volume":"59","author":"K Rojas","year":"2016","unstructured":"Rojas K, Stuckey A. Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol. 2016;59(4):651\u201372.","journal-title":"Clin Obstet Gynecol"},{"issue":"7","key":"2659_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/thoraxjnl-2013-204403","volume":"69","author":"P Clark","year":"2014","unstructured":"Clark P. Protease-mediated ectodomain shedding. Thorax. 2014;69(7):682\u20134.","journal-title":"Thorax"},{"issue":"11","key":"2659_CR24","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1158\/0008-5472.CAN-07-0035","volume":"67","author":"N Hempel","year":"2007","unstructured":"Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res. 2007;67(11):5231\u20138.","journal-title":"Cancer Res"},{"issue":"3","key":"2659_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/0008-5472.CAN-06-3117","volume":"67","author":"RS Turley","year":"2007","unstructured":"Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-\u03b2 receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007;67(3):1090\u20138.","journal-title":"Cancer Res"},{"key":"2659_CR26","doi-asserted-by":"crossref","unstructured":"Ahn JY, Park S, Yun YS, Song JY. Inhibition of type III TGF-\u03b2 receptor aggravates lung fibrotic process. Biomed Pharmacother [Internet]. 2010;64(7):472\u20136. Available from: http:\/\/dx.doi.org\/10.1016\/j.biopha.2010.01.006.","DOI":"10.1016\/j.biopha.2010.01.006"},{"issue":"15","key":"2659_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.201899456","volume":"37","author":"SF Lichtenthaler","year":"2018","unstructured":"Lichtenthaler SF, Lemberg MK, Fluhrer R. Proteolytic ectodomain shedding of membrane proteins in mammals\u2014hardware, concepts, and recent developments. EMBO J. 2018;37(15):1\u201324.","journal-title":"EMBO J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-020-02659-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T08:15:55Z","timestamp":1607674555000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2659"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02659-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-78204\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This prospective observational study was approved by the Ethics Committee of the University Hospital Center Sestre milosrdnice (EP-1402\/18-3). All participants provided a signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"478"}}